RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -1.4 Million USD | -5.53% |
| 2021 | -1.32 Million USD | -2.62% |
| 2020 | -1.29 Million USD | -2.59% |
| 2019 | -1.26 Million USD | 4.65% |
| 2018 | -1.32 Million USD | 8.39% |
| 2017 | -1.44 Million USD | 13.7% |
| 2016 | -1.67 Million USD | 2.08% |
| 2015 | -1.7 Million USD | -9.9% |
| 2014 | -1.55 Million USD | -70.14% |
| 2013 | -914.25 Thousand USD | -8.67% |
| 2012 | -841.33 Thousand USD | 86.0% |
| 2011 | -6.01 Million USD | -19.46% |
| 2010 | -5.03 Million USD | 22.66% |
| 2009 | -6.5 Million USD | 39.68% |
| 2008 | -10.78 Million USD | 8.93% |
| 2007 | -11.84 Million USD | -34.76% |
| 2006 | -8.78 Million USD | -55.03% |
| 2005 | -5.66 Million USD | -69.61% |
| 2004 | -3.34 Million USD | -105.77% |
| 2003 | -1.62 Million USD | -12.4% |
| 2002 | -1.44 Million USD | -191.56% |
| 2001 | -495.69 Thousand USD | -6.96% |
| 2000 | -463.43 Thousand USD | -129.23% |
| 1999 | -202.16 Thousand USD | 65.72% |
| 1998 | -589.82 Thousand USD | 9.95% |
| 1997 | -654.97 Thousand USD | 55.71% |
| 1996 | -1.47 Million USD | 68.59% |
| 1995 | -4.7 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -304.91 Thousand USD | 1.27% |
| 2023 Q2 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 FY | -1.4 Million USD | -5.53% |
| 2022 Q1 | -343.84 Thousand USD | 6.46% |
| 2022 Q2 | -464.84 Thousand USD | -35.19% |
| 2022 Q3 | -284.46 Thousand USD | 38.8% |
| 2022 Q4 | -308.84 Thousand USD | -8.57% |
| 2021 Q2 | -257.44 Thousand USD | 14.02% |
| 2021 Q3 | -404.04 Thousand USD | -56.94% |
| 2021 FY | -1.32 Million USD | -2.62% |
| 2021 Q4 | -367.6 Thousand USD | 9.02% |
| 2021 Q1 | -299.41 Thousand USD | -3.0% |
| 2020 Q4 | -290.7 Thousand USD | -3.66% |
| 2020 FY | -1.29 Million USD | -2.59% |
| 2020 Q1 | -338.14 Thousand USD | -12.5% |
| 2020 Q2 | -385.23 Thousand USD | -13.92% |
| 2020 Q3 | -280.45 Thousand USD | 27.2% |
| 2019 Q3 | -286.49 Thousand USD | 18.6% |
| 2019 Q2 | -351.94 Thousand USD | -9.01% |
| 2019 Q1 | -322.86 Thousand USD | -24.26% |
| 2019 FY | -1.26 Million USD | 4.65% |
| 2019 Q4 | -300.57 Thousand USD | -4.92% |
| 2018 Q2 | -342.1 Thousand USD | 6.05% |
| 2018 Q3 | -357.3 Thousand USD | -4.44% |
| 2018 Q4 | -259.82 Thousand USD | 27.28% |
| 2018 FY | -1.32 Million USD | 8.39% |
| 2018 Q1 | -364.13 Thousand USD | -16.81% |
| 2017 Q4 | -311.73 Thousand USD | 29.5% |
| 2017 Q3 | -442.18 Thousand USD | -45.92% |
| 2017 FY | -1.44 Million USD | 13.7% |
| 2017 Q1 | -387.69 Thousand USD | -12.26% |
| 2017 Q2 | -303.02 Thousand USD | 21.84% |
| 2016 Q3 | -378.57 Thousand USD | 23.93% |
| 2016 Q4 | -345.37 Thousand USD | 8.77% |
| 2016 Q1 | -452.42 Thousand USD | -18.13% |
| 2016 FY | -1.67 Million USD | 2.08% |
| 2016 Q2 | -497.64 Thousand USD | -10.0% |
| 2015 FY | -1.7 Million USD | -9.9% |
| 2015 Q4 | -382.98 Thousand USD | 0.52% |
| 2015 Q1 | -390.97 Thousand USD | -5.07% |
| 2015 Q3 | -384.97 Thousand USD | 30.08% |
| 2015 Q2 | -550.6 Thousand USD | -40.83% |
| 2014 Q1 | -363.55 Thousand USD | -101.12% |
| 2014 Q2 | -406.01 Thousand USD | -11.68% |
| 2014 Q4 | -372.11 Thousand USD | 10.08% |
| 2014 FY | -1.55 Million USD | -70.14% |
| 2014 Q3 | -413.8 Thousand USD | -1.92% |
| 2013 Q3 | -161.63 Thousand USD | 34.42% |
| 2013 Q2 | -246.48 Thousand USD | 24.25% |
| 2013 Q1 | -325.37 Thousand USD | -252.99% |
| 2013 FY | -914.25 Thousand USD | -8.67% |
| 2013 Q4 | -180.76 Thousand USD | -11.83% |
| 2012 Q2 | -225.69 Thousand USD | 47.39% |
| 2012 Q3 | -94.49 Thousand USD | 58.13% |
| 2012 Q4 | -92.17 Thousand USD | 2.45% |
| 2012 FY | -841.33 Thousand USD | 86.0% |
| 2012 Q1 | -428.96 Thousand USD | 50.33% |
| 2011 Q2 | -1.53 Million USD | 4.05% |
| 2011 FY | -6.01 Million USD | -19.46% |
| 2011 Q4 | -863.62 Thousand USD | 57.2% |
| 2011 Q3 | -2.01 Million USD | -31.65% |
| 2011 Q1 | -1.59 Million USD | -73.39% |
| 2010 Q1 | -1.14 Million USD | 10.31% |
| 2010 Q2 | -1.37 Million USD | -19.47% |
| 2010 Q3 | -1.59 Million USD | -15.89% |
| 2010 FY | -5.03 Million USD | 22.66% |
| 2010 Q4 | -921.26 Thousand USD | 42.07% |
| 2009 Q3 | -1.24 Million USD | 15.04% |
| 2009 Q4 | -1.28 Million USD | -3.07% |
| 2009 FY | -6.5 Million USD | 39.68% |
| 2009 Q2 | -1.46 Million USD | 42.0% |
| 2009 Q1 | -2.52 Million USD | 10.04% |
| 2008 Q3 | -2.4 Million USD | 17.19% |
| 2008 Q4 | -2.8 Million USD | -16.58% |
| 2008 FY | -10.78 Million USD | 8.93% |
| 2008 Q2 | -2.9 Million USD | -8.44% |
| 2008 Q1 | -2.67 Million USD | 27.02% |
| 2007 Q2 | -2.73 Million USD | 15.04% |
| 2007 Q4 | -3.66 Million USD | -64.27% |
| 2007 FY | -11.84 Million USD | -34.76% |
| 2007 Q1 | -3.21 Million USD | -89.01% |
| 2007 Q3 | -2.23 Million USD | 18.21% |
| 2006 Q1 | -1.42 Million USD | 37.54% |
| 2006 Q2 | -359.15 Thousand USD | 74.74% |
| 2006 FY | -8.78 Million USD | -55.03% |
| 2006 Q3 | -2.07 Million USD | -478.07% |
| 2006 Q4 | -1.7 Million USD | 18.12% |
| 2005 Q4 | -2.27 Million USD | -56.41% |
| 2005 FY | -5.66 Million USD | -69.61% |
| 2005 Q1 | -925.02 Thousand USD | -11.2% |
| 2005 Q2 | -1.01 Million USD | -9.47% |
| 2005 Q3 | -1.45 Million USD | -43.73% |
| 2004 Q4 | -831.84 Thousand USD | 15.43% |
| 2004 Q2 | -364.4 Thousand USD | 68.66% |
| 2004 Q1 | -1.16 Million USD | -126.94% |
| 2004 FY | -3.34 Million USD | -105.77% |
| 2004 Q3 | -983.61 Thousand USD | -169.92% |
| 2003 Q3 | -390.56 Thousand USD | 9.53% |
| 2003 FY | -1.62 Million USD | -12.4% |
| 2003 Q2 | -431.73 Thousand USD | -48.99% |
| 2003 Q1 | -289.76 Thousand USD | 38.44% |
| 2003 Q4 | -512.42 Thousand USD | -31.2% |
| 2002 Q1 | -136.11 Thousand USD | -17.76% |
| 2002 Q3 | -347.47 Thousand USD | 29.23% |
| 2002 FY | -1.44 Million USD | -191.56% |
| 2002 Q2 | -490.99 Thousand USD | -260.72% |
| 2002 Q4 | -470.68 Thousand USD | -35.46% |
| 2001 Q1 | -141.42 Thousand USD | 17.31% |
| 2001 FY | -495.69 Thousand USD | -6.96% |
| 2001 Q4 | -115.58 Thousand USD | 1.74% |
| 2001 Q3 | -117.63 Thousand USD | 2.83% |
| 2001 Q2 | -121.05 Thousand USD | 14.4% |
| 2000 FY | -463.43 Thousand USD | -129.23% |
| 2000 Q1 | -112.67 Thousand USD | 42.21% |
| 2000 Q2 | -81.44 Thousand USD | 27.71% |
| 2000 Q3 | -98.28 Thousand USD | -20.67% |
| 2000 Q4 | -171.02 Thousand USD | -74.01% |
| 1999 Q1 | -7206.00 USD | 0.0% |
| 1999 Q2 | -389.00 USD | 94.6% |
| 1999 Q3 | -389.00 USD | 0.0% |
| 1999 Q4 | -194.96 Thousand USD | -50018.25% |
| 1999 FY | -202.16 Thousand USD | 65.72% |
| 1998 FY | -589.82 Thousand USD | 9.95% |
| 1997 FY | -654.97 Thousand USD | 55.71% |
| 1996 FY | -1.47 Million USD | 68.59% |
| 1995 FY | -4.7 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -894.976% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -104.089% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -717.442% |
| CytoDyn Inc. | -18.05 Million USD | 92.236% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.623% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -193863.974% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 22.811% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 72.207% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -4580.793% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -672.511% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.555% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.474% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.151% |
| Resverlogix Corp. | -12.74 Million USD | 89.003% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -259.882% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 114.391% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 42.9% |
| Mesoblast Limited | -84.14 Million USD | 98.334% |
| GB Sciences, Inc. | -1.42 Million USD | 1.304% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -104.089% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 92.144% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 58.825% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 78.911% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 55.749% |
| ContraFect Corporation | -56.88 Million USD | 97.536% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 49.034% |
| BioStem Technologies, Inc. | -7.77 Million USD | 81.977% |
| LadRx Corporation | -3.82 Million USD | 63.333% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.166% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -25.29% |
| CSL Limited | 3.7 Billion USD | 100.038% |
| Biomind Labs Inc. | -1 Million USD | -38.866% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -50.528% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.713% |
| Nascent Biotech, Inc. | -2.22 Million USD | 37.127% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.047% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 128.526% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 139.604% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 8.727% |
| Marizyme, Inc. | -34.08 Million USD | 95.887% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 83.21% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -148.262% |
| Zenith Capital Corp. | -8.94 Million USD | 84.323% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 50.816% |
| Halberd Corporation | -75.05 Thousand USD | -1768.076% |
| Genus plc | 6.4 Million USD | 121.906% |
| Pharming Group N.V. | -4.87 Million USD | 71.268% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 29.423% |
| IMV Inc. | -38.67 Million USD | 96.375% |
| Affymax, Inc. | -15.04 Million USD | 90.682% |
| SYBLEU INC | -149.18 Thousand USD | -839.798% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -34.29% |
| Enzolytics Inc. | -2.14 Million USD | 34.755% |
| argenx SE | -425.04 Million USD | 99.67% |
| AVAX Technologies, Inc. | 6.69 Million USD | 120.947% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4.984% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 62.578% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -5470.087% |
| Cell Source, Inc. | -4.32 Million USD | 67.587% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -190.23% |
| Q BioMed Inc. | -3.44 Million USD | 59.311% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 66.922% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -11.623% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 46.642% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 69.219% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.45% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 51.676% |
| Rebus Holdings, Inc. | -664 Thousand USD | -111.143% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -42.471% |
| Skye Bioscience, Inc. | -13.67 Million USD | 89.745% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 24.801% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 30.067% |
| ONE Bio Corp. | 13.68 Million USD | 110.247% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 27.456% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -24.632% |
| Agentix Corp. | -1.37 Million USD | -2.204% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 51.977% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 11.23% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7947.707% |
| Kadimastem Ltd | -3.04 Million USD | 53.886% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -435.671% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -237.44% |
| NovAccess Global Inc. | -2.46 Million USD | 43.165% |
| Itoco Inc. | -919.14 Thousand USD | -52.533% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -537.043% |
| Qrons Inc. | -643.67 Thousand USD | -117.81% |
| Mobile Lads Corp. | -554.55 Thousand USD | -152.816% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.663% |
| International Stem Cell Corporation | -663 Thousand USD | -111.462% |
| Bioxytran, Inc. | -3.82 Million USD | 63.3% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2563.357% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -6792.778% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.134% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 13.35% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -90.531% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 54.934% |
| Neutra Corp. | -229.48 Thousand USD | -510.927% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 92.006% |
| PureTech Health plc | -146.19 Million USD | 99.041% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 93.476% |
| IXICO plc | -1.43 Million USD | 2.436% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 85.228% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.849% |
| CSL Limited | 3.81 Billion USD | 100.037% |
| Cellectis S.A. | -108.85 Million USD | 98.712% |